|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.400 USD | +1.69% |
|
-5.22% | -73.33% |
Company Valuation: Atossa Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 20.32 | - | - |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -73.33% | - | - |
| Enterprise Value (EV) | 202.6 | 66.92 | 110.3 | 118.8 | 76.21 | 20.32 | 20.32 | 20.32 |
| Change | - | -66.97% | 64.77% | 7.71% | -35.83% | -73.33% | 0% | 0% |
| P/E | -8.89x | -2.52x | -3.67x | -4.72x | -2.19x | -0.54x | -0.68x | 0.91x |
| PBR | 1.47x | 0.57x | 1.22x | 1.69x | 1.92x | - | - | - |
| PEG | - | -0.2x | -0.3x | 0.3x | -0.1x | -0.07x | 0x | -0x |
| Capitalization / Revenue | - | - | - | - | - | - | - | 0.17x |
| EV / Revenue | - | - | - | - | - | - | - | 0.17x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.53x | -0.52x | 0.43x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -2.7 | -3.15 | -3.6 | -3 | -4.04 | -4.333 | -3.463 | 2.59 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | 118.7 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.52 | -27.69 | -31.38 | -27.62 | -37.14 | -38.09 | -39.31 | 47.54 |
| Net income 1 | -20.61 | -26.96 | -30.09 | -25.5 | -34.77 | -37.39 | -39.31 | 47.54 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 24.000 | 7.927 | 13.200 | 14.161 | 8.850 | 2.360 | 2.360 | 2.360 |
| Nbr of stocks (in thousands) | 8,442 | 8,442 | 8,354 | 8,387 | 8,611 | 8,611 | - | - |
| Announcement Date | 2/28/22 A | 3/22/23 A | 4/1/24 A | 3/25/25 A | 3/25/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.54x | - | - | - | 20.32M | |
| 32.79x | 5.87x | 17.42x | 1% | 47.74B | |
| -23.47x | 352.2x | -21.51x | -.--% | 39.98B | |
| 48.32x | 4.93x | 31.87x | -.--% | 36.23B | |
| 25.95x | 2.85x | 12.32x | -.--% | 35.59B | |
| 27.91x | 7.98x | 19.84x | 0.43% | 27.91B | |
| 33.62x | 5.49x | 25.05x | -.--% | 16.45B | |
| 22.1x | 1.97x | 8.54x | 1.19% | 13.21B | |
| 23.86x | 1.9x | 11.51x | -.--% | 12.93B | |
| Average | 21.17x | 47.90x | 13.13x | 0.33% | 25.56B | |
| Weighted average by Cap. | 22.75x | 65.23x | 12.14x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ATOS Stock
- Valuation Atossa Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
